Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is a promising investment choice based on their innovative approach to treating metabolic diseases, as evidenced by their authorization for a clinical trial of RJVA-001 and positive results for their weight loss procedure, Revita. The company's plans to expedite FDA approval and explore new classifications for their treatments demonstrate their strong potential for success, but investors should consider the inherent risks of the medical and biotech industry when considering an investment in Fractyl Health.

Bears say

Fractyl Health is facing potential challenges and risks in obtaining regulatory approval and reimbursement for their novel metabolic disease treatments, which could delay their ability to bring products to market and generate revenue. While initial data for their lead product candidate, Revita, and the Rejuva candidate show promise, they are based on small sample sizes and relatively short follow-up periods. Furthermore, the company's timing guidance for pivotal data has been narrowed, putting more pressure on them to deliver positive results in the near future. These factors, combined with a lack of other significant financial data, contribute to a negative outlook on Fractyl Health's stock.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.